Introduction
Exposure to radiation in the context of terrorist attacks or natural disasters produces death within about 10 days reflecting toxicity to the gastrointestinal (GI) tract, constituting the acute radiation-induced GI syndrome (RIGS) (1) (2) (3) . In contrast to radiation-induced bone marrow toxicity, in which death can be prevented by bone marrow transplantation, there are no approved management paradigms to prevent or treat RIGS (4) . Importantly, radiation therapy remains a mainstay in the management of cancer, a leading cause of death worldwide. Radiation therapy destroys rapidly proliferating cancer cells and, inevitably, normal tissues characterized by continuous regeneration programs, including hair follicles, bone marrow, the GI tract as well as other glandular epithelia (5) . In that context, dose-limiting toxicities of radiation discourage patients from completing therapy; restrict maximum doses of radiation which limits the efficacy of treatment; and can lead to chronic morbidity and mortality (5) .
Inadequate management in part reflects an incomplete understanding of mechanisms underlying RIGS. Indeed, critical molecular mechanisms and cellular targets mediating epithelial toxicity underlying RIGS remain controversial (6) (7) (8) (9) (10) (11) (12) (13) (14) . Recent studies suggest that p53 in intestinal epithelial cells principally controls radiation-induced GI toxicity in mice, independently of apoptosis (7) . In that context, deletion of the intrinsic apoptotic pathway from intestinal endothelial or epithelial cells failed to protect mice from GI toxicity-related death (7) . In contrast, tissue-specific targeted deletion of intestinal epithelial cell p53 exacerbates, while its overexpression rescues, RIGS in mice (7, 14) . However, mechanisms underlying radiation-induced intestinal epithelial cell death and intestinal mucosa damage remain undefined (7) . GUCY2C is the intestinal receptor for the endogenous paracrine hormones guanylin (GUCA2A) 5 and uroguanylin (GUCA2B) and the heat-stable enterotoxins (STs) produced by diarrheagenic bacteria (15) (16) (17) . This signaling axis plays a central role in mucosal physiology, regulating fluid and electrolyte secretion (15, 16) , and in coordinating crypt-surface homeostasis, regulating enterocyte proliferation, differentiation, metabolism, apoptosis, DNA repair, and epithelialmesenchymal cross-talk (18) (19) (20) . Further, this axis maintains the intestinal barrier, opposing epithelial injury induced by carcinogens, inflammation, and radiation, and its dysfunction contributes to the pathophysiology of inflammatory bowel disease and tumorigenesis (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) .
While the GUCY2C signaling axis has emerged as one guardian of intestinal epithelial integrity, the role of this axis in responses to lethal radiation, and its utility as a therapeutic target to prevent and treat RIGS remains undefined (22) .
Here, we define a novel role for the GUCY2C paracrine hormone axis in compensatory responses opposing RIGS. Indeed, eliminating GUCY2C signaling amplifies radiation-induced GI toxicity. In that context, durable expression of GUCY2C, GUCA2A, and GUCA2B mRNA and protein is preserved following high doses of radiation that induce RIGS. Moreover, oral administration of the GUYC2C ligand ST opposed RIGS through a p53-dependent mechanism associated with the rescue of intestinal epithelial cells selectively from mitotic catastrophe, but not from apoptosis.
These observations reveal a previously unrecognized compensatory mechanism to epithelial injury induced by high-dose radiation, involving signaling by the GUCY2C paracrine axis that opposes RIGS. They highlight the potential for oral GUCY2C-targeted agents to prevent or treat RIGS in the setting of cancer radiotherapy or environmental exposure through nuclear accident or terrorism. The opportunity to immediately translate these approaches is underscored by the recent regulatory approval of linaclotide (Linzess™) and plecanatide (Trulance™), oral GUCY2C 6 ligands that treat chronic constipation (31) .
Materials and Methods

Animal models
Mice with a targeted germline deletion of GUCY2C (Gucy2c -/-) are well-characterized, and were used after >14 generations of backcrossing onto the C57BL/6 background (15, 16, (18) (19) (20) 26, 32 Supplementary Fig. 1 ) and functionally by radiation-induced mortality ( Supplementary Fig.   2 ). All experiments were carried out with mice that were between 2 to 3.5 months old (mixed males and females) and all mice were on mixed genetic backgrounds as described above and in Supplementary Figure 3 . Where appropriate, age-matched and littermate controls were utilized to minimize the effect of genetic backgrounds. C57BL/6 mice used in oral ST or control peptide supplementation studies were obtained from NIH (NCI-Frederick) while those used for GUCY2C and ligand expression analysis were obtained from the Jackson Laboratory (Bar Harbor, ME). This study was approved by the Institutional Animal Care and Use Committee of Thomas Jefferson University (protocol 01518).
Gamma irradiation-induced GI toxicity
Anesthetized mice were irradiated with total-body gamma irradiation (TBI) or with back limbs to 
Reagents
McCoy's 5A and Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum and other reagents for cell culture were obtained from Life Technologies (Rockville, MD). Bromoguanosine 3', 5'-cyclic monophosphate (8-Br-cGMP), a cell-permeant analog of cGMP, was obtained from Sigma (St. Louis, MO) and 500 µM was used in all experiments (18, 20, 25, 26, 34) .
Cell lines
C57BL/6-derived EL4 lymphoma cells (lymphoblasts in mouse thymus; thymoma), C57BL/6-derived B16 melanoma cells, and HCT116 (wild-type p53) human colon cancer cells, which lack GUCY2C ( Supplementary Fig. 4) (19, 34, 35) The antibody to GUCY2C was validated previously (25, 26) . Antisera to GUCA2A and GUCA2B were generously provided by Dr. Michael Goy (University of North Carolina, Chapel Hill, NC) (37, 38) .
Secondary antibodies conjugated to horseradish peroxidase were from Jackson Immunoresearch Laboratories (West Grove, PA). Staining intensity of specific bands quantified by densitometry was normalized to that for GAPDH using a Kodak imaging system. Average relative intensity reflects the mean of at least three animals in each group and the mean of at least two independent experiments. Molecular weight markers (Cat. # 10748010, 5 µL per run, or Cat. 
Immunohistochemistry and immunofluorescence
Antigens were unmasked in paraffin-embedded sections (5 μm) by heating at 100 o C for 10 min in 10 mM citric buffer, ph 6.0. In addition to those already described, antibodies to antigens probed here included: phosphorylated histone H2AX from Cell Signaling (cat. # 2577, 1:200 dilution), or from Millipore (cat. #05-636, 1:1000 dilution), cleaved caspase 3 from Cell Signaling (cat. # 9579, 1:200 dilution), and β-catenin from Santa Cruz (cat. # sc-7199, 1:50 dilution). The antibody to GUCY2C (25, 26) and the antisera to GUCA2A and GUCA2B were described previously (37, 38) . Fluorescent secondary antibodies were from Invitrogen. Tyramide signal amplification was used to detect GUCY2C and GUCA2A; secondary antibodies conjugated to horseradish peroxidase were from Jackson Immunoresearch Laboratories (cat #115-035-206 and #111-036-046, 1:1000 dilution), and fluorescein-conjugated tyramine was prepared from tyramine HCl (cat #T2879, Sigma) and NHS-fluorescein (cat #46410, Thermo Scientific) (39) Iterative restoration was performed using LSM Image Brower (Zeiss), and images represent three to four merged planes in the z axis. Abnormal anaphase chromatids were counted if cells contained more than two centrosomes or two centrosomes located in the same direction to the spindle midzone separated from kinetochores at the poles.
Quantitative RT-PCR analysis
Transcripts for GUCY2C, GUCA2A, and GUCA2B were quantified by RT-PCR employing primers and conditions described previously (25, 26) .
I-labeled ST binding
Binding of 125 I-labeled ST to GUCY2C was performed as described previously (33) . Briefly, membranes were prepared from cells as described previously (33) 
Results
Silencing GUCY2C exacerbates RIGS. A role for GUCY2C in opposing epithelial cell apoptosis
induced by low doses of ionizing radiation (22) suggested that this receptor may play a role in RIGS. Targeted germline deletion of Gucy2c (Gucy2c -/-mice) (15, 16, (18) (19) (20) 26, 32) accelerated the death of mice following exposure to a lethal dose (high dose, 15 Gy) of total body irradiation (TBI; Fig. 1A ). This dose of radiation produced death by inducing RIGS which could not be rescued by bone marrow transplantation, in contrast to low dose (8 Gy) radiation which produced the hematopoietic, but not the GI, syndrome (Fig. 1B) . Similarly, silencing GUCY2C signaling exacerbated acute GI toxicity quantified by diarrhea (Fig. 1C ) and decreased survival (Fig. 1D) following 18 Gy sub-total abdominal irradiation (STBI), with bone marrow preservation by shielding. Exacerbation of RIGS in the absence of GUCY2C signaling was associated with increased intestinal dysfunction, including weight loss (Fig. 1E), intestinal bleeding (Fig. 1F) , debilitation (untidy fur, Fig. 1G ) (40) , and stool water accumulation (Fig. 1H) (41) . Silencing GUCY2C signaling 14 amplified intestinal epithelial disruption, quantified as crypt loss, produced by STBI in small intestine ( Fig. 1I-J) . Moreover, it created novel epithelial vulnerability in the colon, which is relatively resistant to RIGS (Fig. 1K-L) (1-5) . Together, these observations reveal that the GUCY2C signaling axis plays a compensatory role in modulating mechanisms contributing to RIGS.
GI-toxic irradiation preserves durable expression of GUCY2C and its paracrine hormones. A role
for the GUCY2C paracrine hormone axis in compensatory mechanisms opposing RIGS is predicated on the persistence of expression of the receptor and its hormones following high doses of radiation. Indeed, GUCY2C mRNA and protein, characteristically expressed along the entire crypt-villus axis (17) , was durably preserved following lethal TBI ( Fig. 2A , B, C), a result that is similar to other conditions disrupting epithelial integrity, including tumorigenesis (18) (19) (20) 25) .
Unexpectedly, GI-toxic TBI preserved expression of GUCA2A (Fig. 2D , E, F) and GUCA2B (Fig. 2G,   H, I ), in contrast to other modes of disrupting epithelial integrity, including tumorigenesis, inflammatory bowel disease, and metabolic stress in which ligand expression is lost (18-21,25,26) .
Indeed, expression of GUCA2A, which is low in small intestine, was retained primarily in isolated epithelial cells, as described previously (42). In contrast, expression of GUCA2B, which is the predominant GUCY2C hormone in the small intestine, was retained principally by differentiated epithelial cells in distal villi (42). Preservation of receptor and hormone expression was durable, and there were no significant differences in mRNA or protein levels across the time course of injury response ( Fig. 2; Supplementary Fig. 5 ). Moreover, preservation of hormone expression was independent of GUCY2C expression (Supplementary Fig. 6 ). These observations are consistent with a role for the GUCY2C paracrine hormone signaling axis in compensatory responses that oppose acute radiation-induced GI toxicity. Moreover, the persistence of receptor 15 expression across the continuum of injury response suggests the potential utility of GUCY2C as a therapeutic target to prevent RIGS.
GUCY2C activation by oral ligand rescues RIGS, but not extra-GI tumor responses to radiation.
In wild type mice, oral administration of ST, an exogenous GUCY2C ligand, reduced morbidity and mortality induced by STBI, quantified by the incidence of diarrhea (Fig. 3A) and survival (Fig. 3B) respectively. Similarly, oral ST opposed STBI-induced intestinal dysfunction, including weight loss (Fig. 3C), intestinal bleeding (Fig. 3D), debilitation (Fig. 3E) , and stool water accumulation (Fig. 3F) .
Further, oral ST rescued intestinal morphology and stool formation (Fig. 3G) , and water reabsorption associated with preservation of normal histology (Fig. 3H ) after STBI. In contrast, oral ST did not rescue RIGS in Gucy2c -/-mice ( Supplementary Fig. 7) . Furthermore, oral ST did not alter therapeutic radiation responses of radiation-sensitive thymoma or radiation-resistant melanoma (Fig. 3I) . Moreover, chronic oral ST was safe, without adverse pharmacological effects like diarrhea (Fig. 3J) or growth retardation (Fig. 3K ). These observations support the suggestion that GUCY2C signaling comprises a compensatory mechanism opposing RIGS that can be engaged by orally administered ligands. Indeed, GUCY2C ligands safely protect intestinal epithelial cells specifically (26), without altering therapeutic responses to radiation of tumors outside the intestine.
GUCY2C signaling opposing RIGS requires p53. GUCY2C signaling protects intestinal epithelial cells from apoptosis induced by low dose radiation (22) . However, while silencing GUCY2C signaling increased basal levels of apoptosis in small intestine, as demonstrated previously (18), it did not alter apoptosis associated with RIGS along the rostral-caudal axis of the intestine across the continuum of injury responses (Fig. 4A) . In that context, p53 also opposes RIGS through 16 mechanisms that are independent of apoptosis ( Supplementary Fig. 8) (7) . Indeed, eliminating p53 phenocopied GUCY2C silencing, exacerbating RIGS-related mortality ( Fig. 1D; Supplementary   Fig. 2) . Further, activation of GUCY2C with oral ST improved survival in wild type, but not p53 int-/-, mice following STBI (Fig. 4B) . Moreover, GUCY2C activation opposed STBI-induced intestinal dysfunction quantified by body weight loss (Fig. 4C), intestinal bleeding (Fig. 4D) and debilitation ( Fig. 4E ) in wild type, but not in p53 int-/-, mice. These observations suggest that the GUCY2C signaling axis opposes RIGS through a mechanism requiring p53.
GUCY2C signaling opposing RIGS is associated with amplification of p53 responses. Consistent with a role for p53 in mediating the effects of GUCY2C signaling on radiation-induced intestinal toxicity, oral ST increased levels of phosphorylated p53 in mouse intestinal epithelial cells in RIGS induced by STBI (Fig. 4F ). Recapitulating these in vivo results, the GUCY2C second messenger, cGMP, increased total and phosphorylated p53 induced by radiation in HCT116 human colon carcinoma cells (Fig. 4G) , an in vitro model of intestinal epithelial cells that express wild type p53, but not GUCY2C (19, 34, 35) (Supplementary Fig. 4) . Amplification of p53 responses to radiation induced by cGMP signaling in HCT116 cells was associated with reduced interactions between p53 and the inhibitory protein Mdm2 (Fig. 4H) .
GUCY2C signaling opposing RIGS is associated with p53-dependent rescue of mitotic catastrophe. Induction of GUCY2C signaling by oral ST opposed chromosomal instability in intestinal epithelial cells following STBI, reducing double-strand DNA breaks (Fig. 5A ) and abnormal mitoses characteristically associated with mitotic catastrophe (Fig. 5B) . Similarly, chromosomal instability produced by irradiation, quantified by centrosome counts or the anaphase bridge index (43) , was reduced in HCT116 cells treated with 8-Br-cGMP (Fig. 5C-D) . In 17 contrast, elimination of p53 (HCT116 p53 -/-) amplified chromosomal instability produced by irradiation, and this damage was insensitive to 8-Br-cGMP (Fig. 5C-D) . Moreover, cell death by mitotic catastrophe reflecting radiation-induced aberrant mitosis was reduced by cGMP in parental, but not in p53 -/-, HCT116 cells (Fig. 5E) .
DISCUSSION
RIGS reflects radiation-induced genotoxic stress in intestinal epithelial cells (7) (8) (9) 11, 12, 14) .
Radiation produces DNA damage, directly and through reactive oxygen species (23), activating p53 (7, 9, 14, 44) . In turn, p53 mediates a bifurcated injury response. Cells damaged beyond repair undergo caspase-dependent apoptosis initiated by p53 activation of PUMA (6, 9, 12, 13) . Further, in cells that can be rescued, p53 induces the expression of p21, a key inhibitor of cyclindependent kinases which regulates cell cycle checkpoints (7, 9, 14) . Inhibition of proliferation associated with these checkpoints permits cells to repair damaged DNA (7) (8) (9) 12, 14, 45) . However, p53 responses are limited and cells with damaged DNA escape checkpoints within days of irradiation, enter prematurely into the cell cycle with damaged DNA, and undergo mitotic catastrophe (7, 9, 12, 14, 46) . In turn, this produces epithelial loss and mucositis, disrupting barrier function associated with fluid and electrolyte loss and infection which are principle mechanisms of death from RIGS (47) . Here, we reveal an unexpected compensatory mechanism that opposes this pathophysiology, involving the GUCY2C signaling axis at the intersection of radiation injury and p53 responses. GUCY2C is selectively expressed by intestinal epithelial cells and activation by the endogenous hormones guanylin and uroguanylin, or the diarrheagenic bacterial STs, increases intracellular cGMP accumulation (17) . While there is evidence for GUCY2C signaling in other tissues (32, 48) , 18 the effect of oral ST in ameliorating RIGS in the present study is consistent with a primary effect on intestinal receptors, reflecting the absence of bioavailability of oral GUCY2C ligands (31) .
GUCY2C-cGMP signaling modulates intestinal secretion, one mechanism by which bacteria induce diarrhea, and the oral GUCY2C ligands linaclotide (Linzess ™ ) and plecanatide (Trulance™) improve constipation and relieve abdominal pain in patients with irritable bowel syndrome (31, 49) . Further, GUCY2C signaling regulates proliferation and DNA damage repair, processes that are canonically disrupted in RIGS (26). Indeed, signaling through the GUCY2C-cGMP axis inhibits DNA synthesis and prolongs the cell cycle, imposing a G1-S delay in part by regulating p21, key injury responses to radiation (18) (19) (20) 50) . Further, silencing GUCY2C increases DNA oxidation and double strand breaks, amplifying mutations induced by chemical or genetic DNA damage, reflecting ROS and inadequate repair (20) . Moreover, silencing GUCY2C disrupts the intestinal barrier (26), a key pathophysiological mechanism contributing to RIGS (47) . Conversely, GUCY2C ligands block that damage, enhancing barrier integrity and accelerating recovery from injury (23, 24, 26, 27, 30) . This role in promoting mucosal barrier integrity supports GUCY2C as a therapeutic target for RIGS.
The present observations suggest a previously unrecognized compensatory mechanism opposing RIGS in which the paracrine hormones guanylin and uroguanylin activate GUCY2C-cGMP signaling to defend the integrity of the intestinal epithelial barrier. In that model, paracrine hormone stimulation of the GUCY2C-cGMP signaling axis supports p53 responses to radiation injury by disrupting interactions with Mdm2, a key regulator of responses to genotoxic stress which binds to the amino terminal of 18-19.p53 , inhibiting its transactivation function and targeting it for proteasomal degradation (45, 51, 52) . In turn, amplified p53 responses contribute to resolving 19 DNA damage, limiting mitotic catastrophe (7) . Beyond these compensatory responses, the durable preservation of GUCY2C expression following high dose irradiation across the rostralcaudal axis of the intestine and the continuum of injury responses offers an opportunity to target this receptor for mitigation of RIGS by oral GUCY2C hormone administration. Indeed, it creates the unique possibility of transforming RIGS from a syndrome of irreversible DNA damage to one that can be reversed or prevented by oral GUCY2C ligand supplementation.
These studies stand in contradistinction to other models of intestinal injury in which homeostasis is disrupted through paracrine hormone loss silencing GUCY2C. Indeed, guanylin and uroguanylin are the most commonly lost gene products in sporadic colorectal cancer and these hormones are lost at the earliest stages of neoplasia (29, 53, 54) . Hormone loss silences the GUCY2C signaling axis and interrupts canonical homeostatic mechanisms that regulate the continuously regenerating intestinal epithelium and whose disruption is essential for tumorigenesis (17) (18) (19) (20) 25, 26, 34) . Similarly, while obesity and colorectal cancer are associated, underlying mechanisms have remained unclear. Recent studies revealed that over-consumption of calories, which is an essential mechanism contributing to obesity, produces ER stress leading to guanylin loss silencing the GUCY2C tumor suppressor (25) . Indeed, replacing guanylin suppressed by calories eliminated tumorigenesis (25) . Moreover, oral dextran sulfate injures intestinal mucosa, producing inflammatory bowel disease (IBD), and silencing GUCY2C amplifies injury in IBD, increasing mortality in mice (24, 26, 30) . Indeed, IBD is associated with GUCY2C paracrine hormone loss in humans (21) . In the context of this emerging paradigm of intestinal epithelial injury, the present results demonstrating the preservation of paracrine hormone expression in 20 the context of high dose irradiation was unexpected. However, they are consistent with a role for the GUCY2C paracrine hormone axis in compensatory mechanisms opposing RIGS.
Previous studies revealed that silencing GUCY2C amplified apoptosis induced by low doses of radiation (5 Gy) (22) . These radiation doses are below GI-toxic levels which produce RIGS or bone marrow failure. Further, silencing GUCY2C (Gucy2c -/-mice) did not alter the induction of apoptosis in small or large intestine in RIGS, in contrast to those earlier studies (see Fig. 4A ).
Moreover, silencing GUCY2C recapitulated the effects of eliminating p53 signaling (p53 -/-mice), which also had no effect on apoptosis in small or large intestine in RIGS as reported previously (see Supplementary Fig. 8 ) (7) . In the context of the role of GUCY2C in optimizing p53 injury responses, reinforced by the ability of Gucy2c -/-mice to phenocopy p53 -/-mice (see Supplementary Fig. 2) (7) , the primary mechanism amplifying epithelial disruption in RIGS in the absence of GUCY2C appears to be mitotic catastrophe, rather than apoptosis.
Targeting p53 directly to prevent and treat RIGS has been uniquely challenging and treatments exploiting this mechanism have not yet emerged (7, 9, 12, 14) . The therapeutic challenge arises from the paradoxically opposite roles of p53 in RIGS and the radiation-induced hematopoietic syndrome, the two principal toxicities associated with radiation. Protection of epithelial cells by p53 has made its activation a target to treat RIGS (7) (8) (9) 14, 46) . In striking contrast, radiation toxicity mediated by p53 in bone marrow has made its inhibition a target to treat the hematopoietic syndrome (8, 46, 55) . Hence, p53 has remained an elusive target, requiring tissuespecific strategies for appropriate directional regulation. The present study provides insights into novel molecular mechanisms underlying the pathophysiology of RIGS that can be readily translated into p53-targeted medical countermeasures to prevent and treat acute radiation- 21 induced GI toxicity. Thus, GUCY2C has a narrow tissue distribution, selectively expressed by intestinal epithelial cells from the duodenum to the rectum (15) (16) (17) . Further, GUCY2C is anatomically privileged, expressed in lumenal membranes of those cells, directly accessible to oral agents but inaccessible to the systemic compartment (17, 31) . Moreover, linaclotide (Linzess™) and plecanatide (Trulance™) are oral GUCY2C ligands recently approved for the treatment of chronic constipation syndromes, with negligible oral bioavailability or bioactivity outside the GI tract (31) . The anatomical privilege of GUCY2C coupled with the compartmentalized activity of linaclotide and plecanatide, confined only to the intestinal lumen, offers a uniquely targeted approach to specifically engage p53-dependent mechanisms, compared to other available approaches, to prevent and treat RIGS. In turn, this offers prophylactic and therapeutic solutions to civilians, first-responders, and military personnel at risk from radiation disasters, like Chernobyl or Fukushima. Similarly, it provides a clinically-tractable approach for targeted prevention of GI toxicity from abdominopelvic radiotherapy for cancer, reducing dose-limiting toxicities and permitting greater radiation fractions to be administered, without altering the therapeutic radiosensitivity of extra-intestinal tumors (see Fig. 3I ) (5) .
